Product Reports Resources Pricing Login Book a demo

Avidity Biosciences

Biotech & Life Sciences · San Diego, United States · Founded 2013 · IPO 2020

Research, development, and manufacturing of drug candidates which include antibody-sirna complexes

Valuation $12B
Revenue $8.0M

Investors

18 investors on Avidity Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 18 investors entered at this stage
Takeda
Cormorant Asset Management
F-Prime
Brace Pharma
Janus Henderson Investors
Alethea Capital Management
Adage Capital
Farallon Capital Management
Eli Lilly
Perceptive Advisors
EcoR1 Capital
Wellington Management
Boxer Capital
Casdin Capital
Logos Capital
Moore Venture Partners
RA Capital Management
RTW Investments

Global footprint

Where Avidity Biosciences has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
16K monthly visits
across markets
🇺🇸 United States69.4%
🇬🇧 United Kingdom11.3%
🇮🇳 India8.8%
🇯🇵 Japan5%
🇫🇷 France3.1%
Top 5 markets shown

Talent graph

The shape of Avidity Biosciences's talent

Dealroom maps Avidity Biosciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

7 standout operatorsDealroom-flagged across the org
4 AI specialistsincl. 1 core researchers
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Avidity Biosciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$56M patent portfolio · 39 active families

Estimated portfolio value
$56M
0.47% of market cap · 14× smaller than top peer BioNTech ($788M)
39 active patent families
Where Avidity Biosciences innovates Antiendomysial antibodiesBiochemistryDiseaseMoietyMolecular biology

Where Avidity Biosciences concentrates vs peers

Each axis is a top-10 topic across Avidity Biosciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Avidity Biosciences

An AI-synthesized read of the highest-engagement posts about Avidity Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Avidity Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.